We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blocking a Long Noncoding RNA Reduces Stroke Damage in Rat Model

By LabMedica International staff writers
Posted on 29 Dec 2015
Print article
Image: Brain damage is outlined in red for rats that were treated to block one type of RNA (right), compared to controls (left) (Photo courtesy of Raghu Vemuganti, Suresh Mehta and TaeHee Kim, University of Wisconsin-Madison).
Image: Brain damage is outlined in red for rats that were treated to block one type of RNA (right), compared to controls (left) (Photo courtesy of Raghu Vemuganti, Suresh Mehta and TaeHee Kim, University of Wisconsin-Madison).
By preventing expression of a long noncoding RNA (lncRNA) following induced stroke in a rat model, neurosciences researchers were able to limit damage to the brain and reduce the severity of post-stroke symptoms.

Long noncoding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

In addition to protein-coding RNAs, many classes of noncoding RNAs, including lncRNAs, undergo changes in the brain following a stroke. To better understand the roll of non-coding RNAs in stroke, investigators at the University of Wisconsin-Madison (USA) evaluated the functional significance of an lncRNA called FosDT (Fos downstream transcript) that is coded on the same chromosome as the FOS gene (FBJ murine osteosarcoma viral oncogene homolog). The FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. In some cases, expression of the FOS gene has also been associated with apoptotic cell death.

In the current study, ischemic stroke was induced in laboratory rats by blocking an artery in the brain for one hour. Some of the animals were treated with anti-sense RNA that blocked the production of the lncRNA FosDT.

Results published in the December 16, 2015, issue of the Journal of Neuroscience revealed that stroke induced production of FOS and FosDT in the untreated animals. In the treated animals FosDT knockdown significantly ameliorated post-ischemic motor deficits and reduced the infarct volume. These effects of FosDT in part were due to its interactions with chromatin-modifying proteins Sin3a and coREST (corepressors of the transcription factor REST) and subsequent derepression of REST-downstream genes GRIA2, NFkappaB2, and GRIN1.

"Stroke influences the expression of all types of RNA, and this RNA has a broad influence throughout the cell after the blood supply is restored, in what we call reperfusion injury," said senior author Dr. Raghu Vemuganti, professor of neurological surgery at the University of Wisconsin-Madison. "A few years ago, our lab started to look at how stroke affects noncoding RNA. Two years ago, we identified about 200 types of various lncRNAs that greatly increase or decrease after stroke, and zeroed in on one that we named FosDT. We knew that the level of FosDT went up more than tenfold in the rat brain within three hours after the stroke. We thought, if we block FosDT after the stroke, would it make any difference in the amount of structural damage or behavioral disability?"

"We did not change the initial insult, caused by lack of oxygen," said Dr. Vemuganti, "but this targeted approach greatly reduced the damage after one week. We cannot completely reverse the post-stroke damage, but the total damage decreased by one-third. If we can protect this much brain tissue from stroke, that would be an enormous improvement."

Related Links:

University of Wisconsin-Madison


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.